Japan Nuclear Medicine Market Size & Outlook, 2025-2030

The nuclear medicine market in Japan is expected to reach a projected revenue of US$ 1,373.5 million by 2030. A compound annual growth rate of 12.6% is expected of Japan nuclear medicine market from 2025 to 2030.
Revenue, 2024 (US$M)
$632.2
Forecast, 2030 (US$M)
$1,373.5
CAGR, 2025 - 2030
12.6%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan nuclear medicine market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan nuclear medicine market highlights

  • The Japan nuclear medicine market generated a revenue of USD 972.6 million in 2024 and is expected to reach USD 1,592.1 million by 2030.
  • The Japan market is expected to grow at a CAGR of 8.6% from 2025 to 2030.
  • In terms of segment, diagnostics was the largest revenue generating product in 2024.
  • Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.

Nuclear medicine market data book summary

Market revenue in 2024USD 972.6 million
Market revenue in 2030USD 1,592.1 million
Growth rate8.6% (CAGR from 2025 to 2030)
Largest segmentDiagnostics
Fastest growing segmentDiagnostics
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationDiagnostics, Therapeutics
Key market players worldwideGE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc

Other key industry trends

  • In terms of revenue, Japan accounted for 4.4% of the global nuclear medicine market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China nuclear medicine market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,686.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Nuclear Medicine Market Companies

Name Profile # Employees HQ Website
Abliva AB View profile 6 Scheeletorget 1, Medicon Village, Lund, Sweden, 223 81 https://www.abliva.com
Iren SpA View profile 10000 Via Nubi di Magellano, 30, Reggio Emilia, Italy, 42123 https://www.gruppoiren.it
Jubilant Pharmova View profile 10001+ Noida, Uttar Pradesh, India, Asia https://www.jubilantpharmova.com
Lantheus Holdings Inc View profile 834 201 Burlington Road, South Building, Bedford, MA, United States, 01730 https://www.lantheus.com
Bracco View profile 1001-5000 Milan, Lombardia, Italy, Europe https://www.bracco.com
Nordion View profile 251-500 Kanata, Ontario, Canada, North America http://nordion.com
Eckert & Ziegler Bebig SA View profile 501-1000 Seneffe, Hainaut, Belgium, Europe http://www.ezag.com/home/
Mallinckrodt PLC Ordinary Shares - New View profile 2700 College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 https://www.mallinckrodt.com
Cardinal Health Inc View profile 48000 7000 Cardinal Place, Dublin, OH, United States, 43017 https://www.cardinalhealth.com
GE HealthCare Technologies Inc Common Stock View profile 51000 500 West Monroe Street, Chicago, IL, United States, 60661 https://www.gehealthcare.com

Japan nuclear medicine market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.


Diagnostics was the largest segment with a revenue share of 76.56% in 2024. Horizon Databook has segmented the Japan nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.


The market in Japan is expected to witness a significant growth during the forecast period owing to increasing number of initiatives undertaken by government organizations. For instance, the Japan Radioisotope Association (JRIA) intends to promote effective use of radioisotopes and provide better quality of life. According to investigations by JRIA, the demand for higher quality scans is increasing.

On the other hand, for SPECT, the number is about a million annually. Mo-99 in Japan is imported from other countries; hence, the supply is limited in the country. Therefore, in June 2018, JRIA formed the Japan Foundation of Medical Isotope Development (JAFMID) to promote the domestic production of technetium acid.

For instance, in December 2019, Fuzionaire Radioisotope Technologies K.K. (Fuzionaire Dx) and Department of Nuclear Medicine and Tracer Kinetics at Osaka University entered into a collaborative research agreement to drive the discovery of novel radiotherapeutic agents for the treatment of cancer.

Reasons to subscribe to Japan nuclear medicine market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan nuclear medicine market databook

  • Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Japan nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan Diagnostics - Nuclear Medicine Market, 2024 - 2030 (US$M)

Japan Nuclear Medicine Market Outlook Share, 2024 & 2030 (US$M)

Japan Diagnostics - Nuclear Medicine Market, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online